<DOC>
	<DOCNO>NCT00003588</DOCNO>
	<brief_summary>Phase I trial study effectiveness gene therapy treat patient ovarian cancer respond previous treatment . Inserting p53 gene person 's cancer cell may improve body 's ability fight cancer make cancer cell sensitive treatment .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dos adenovirus p53 patient platinum- paclitaxel-resistant ovarian epithelial cancer . II . Determine qualitative quantitative toxic effect regimen patient . III . Document observe anti-tumor activity regimen patient . IV . Evaluate biological endpoint ( e.g. , induction apoptosis , p53 expression ) regimen patient . OUTLINE : This dose escalation study . Patients undergo laparoscopy p53 assessment catheter placement . Patients receive daily intraperitoneal injection adenovirus p53 ( Ad-p53 ) 5 day every 3 week . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat dose level Ad-p53 . The maximum tolerate dose define dose 1 6 patient experience dose limit toxicity .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic ovarian epithelial cancer platinum paclitaxel resistant define : Disease progression firstline regimen contain platinum drug paclitaxel OR Tumor progression within 6 month completion platinumbased therapy ( either first secondline ) paclitaxelbased therapy ( either first secondline ) Refractory recurrent ovarian epithelial cancer define : Lesions diameter Nonmeasurable disease ( CA125 least 35 ) Ascites and/or pleural effusion allow No borderline low malignant potential tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Bilirubin great 1.5 mg/dL PT/PTT normal Creatinine great 1.4 mg/dL No active , unresolved upper respiratory infection Not HIV positive At least 5 year since prior malignancy , except nonmelanomatous skin cancer Willing able undergo placement Tenckhoff catheter peritoneal cavity sample ascites peritoneal fluid No concurrent serious medical illness No untreated gastrointestinal obstruction Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : May fail unlimited number prior chemotherapy regimen At least 30 day since prior chemotherapy No prior radiotherapy pelvis abdomen Eligible laparoscopy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>